Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Waste Management, Inc. — how do they compare? Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B), while Waste Management, Inc. trades at $226.76 (market cap $90.58B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Waste Management, Inc. pays a 1.56% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | WM | |
|---|---|---|
Market Cap | $132.79B | $90.58B |
Sector | Health | Industrials |
52-Week High | $529.65 | $246.51 |
52-Week Low | $376.62 | $196.77 |
Enterprise Value | $126.92B | $113.37B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
WM trades at $227.68, down 0.58% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $2.02, beating estimates, with revenue growth to $25.2 billion in 2025. Valuation ratios are elevated, with a P/E of 59.96 and P/S of 16.1, reflecting premium pricing. Recent news highlights margin gains and institutional activity, including Bank of America reducing holdings by 6.1% in Q1 2026 (Defense World, 2026-08-01).
The outlook remains positive with a consensus price target of $263.43, implying 15.7% upside, driven by pricing discipline and technology investments. Risks include high debt levels, with a debt-to-asset ratio of 53.62% in 2024, and softer volume trends. Earnings momentum from recent beats supports growth, but margin pressures and economic sensitivity could limit gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
